Why Sun Pharma is up today? - Reasons explained

27 Apr 2026 , 12:53 PM

Sun Pharmaceutical Industries Limited has emerged as a top gainer on the National Stock Exchange of India (NSE), with its stock trading at ₹1,733.00, up nearly 7% intraday. The surge follows the company’s announcement of a major global acquisition—buying Organon & Co. in an all-cash deal valued at approximately $11.75 billion.

Deal Overview: Sun Pharma–Organon Acquisition

Sun Pharma will acquire Organon through a merger executed via one of its subsidiaries. The deal is priced at $14 per share and is expected to close in early 2027, subject to regulatory and shareholder approvals.

Key highlights:

• Deal size: ~$11.75 billion (enterprise value)
• Structure: Subsidiary-led merger
• Payment: All-cash transaction
• Expected closure: Early 2027

Strategic Rationale Behind the Acquisition

This acquisition marks a transformative step for Sun Pharma as it aims to strengthen its global footprint and diversify its product portfolio.

Key strategic benefits:

• Entry into biosimilars, positioning Sun Pharma among the top 10 global players in this segment
• Expansion in women’s health, making it one of the top three globally
• Increased contribution from innovative medicines (projected 27% of revenue post-deal)
• Presence in over 150 countries

The move aligns with Sun Pharma’s long-term vision of becoming a globally dominant pharmaceutical company.

Combined Company: Stronger Global Positioning

Post-acquisition, the combined entity is expected to rank among the top 25 pharmaceutical companies globally, with an estimated revenue of $12.4 billion.

Strengthened segments:

• Branded generics and established medicines
• Women’s health portfolio
• Biosimilars

The merged company will also have a strong geographic presence, with 18 major markets each generating over $100 million in revenue.

Financial Impact and Funding Structure

Organon reported strong financials for FY2025, making it a valuable addition to Sun Pharma’s portfolio.

Organon Financial Snapshot:

• Revenue: $6.2 billion
• Adjusted EBITDA: $1.9 billion

Post-deal expectations:

• EBITDA and cash flow are expected to nearly double
• Net debt-to-EBITDA ratio projected at ~2.3x initially
• Gradual deleveraging planned

Funding:

The acquisition will be financed through a combination of internal cash reserves and bank financing.

Synergies and Growth Opportunities

The deal unlocks multiple synergies that could drive long-term growth:

• Expanded product portfolio across key therapeutic areas
• Cross-market penetration leveraging combined global presence
• Access to Organon’s footprint in over 140 countries
• Integration of talent and manufacturing capabilities
• Enhanced attractiveness as a partner for new product launches

About Organon & Co.

Organon & Co. is a global healthcare company focused on improving women’s health.

Key facts:

• Spun off from Merck & Co. in 2021
• Portfolio includes 70+ products
• Core focus areas:
  • Women’s health
  • Biosimilars
  • General medicines
• Manufacturing footprint: 6 facilities across Europe and emerging markets

The acquisition is subject to several approvals before completion:

• Regulatory clearances across multiple jurisdictions
• Approval from Organon shareholders
• Final closing conditions

Sun Pharma has confirmed that board approvals have already been secured.

Market Reaction and Leadership Outlook

Investors have responded positively to the announcement, pushing Sun Pharma’s stock significantly higher on the NSE.

Leadership insights:

• Sun Pharma emphasized growth, diversification, and global expansion
• Organon highlighted immediate shareholder value and strong strategic alignment

 

The acquisition of Organon marks a pivotal moment for Sun Pharmaceutical Industries Limited. By expanding into biosimilars and strengthening its presence in women’s health, the company is positioning itself as a global pharmaceutical powerhouse.

With strong financial synergies, expanded global reach, and a diversified portfolio, this deal could reshape the competitive landscape of the pharmaceutical industry in the coming years.